SEARCH

SEARCH BY CITATION

References

  • Adlersberg M., Arango V., Hsiung S., Mann J. J., Underwood M. D., Liu K., Kassir S. A., Ruggiero D. A. and Tamir H. (2000) In vitro autoradiography of serotonin 5-HT (2A/2C) receptor-activated G protein: guanosine-5′-(gamma-[(35)S]thio)triphosphate binding in rat brain. J. Neurosci. Res. 61, 674685.
  • Ameri A. (1999) The effects of cannabinoids on the brain. Prog. Neurobiol. 58, 315348.
  • Artigas F., Romero L., De Montigny C. and Blier P. (1996) Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci. 19, 378383.
  • Barnes N. M. and Sharp T. (1999) A review of central 5-HT receptors and their function. Neuropharmacology 38, 10831152.
  • Bert B., Fink H., Hortnagl H., Veh R. W., Davies B., Theuring F. and Kusserow H. (2006) Mice over-expressing the 5-HT(1A) receptor in cortex and dentate gyrus display exaggerated locomotor and hypothermic response to 8-OH-DPAT. Behav. Brain Res. 167, 328341.
  • Blier P. and Ward N. M. (2003) Is there a role for 5-HT1A agonists in the treatment of depression? Biol. Psychiatry 53, 193203.
  • Blier P., Seletti B., Gilbert F., Young S. N. and Benkelfat C. (2006) Serotonin 1A receptor activation and hypothermia in humans: lack of evidence for a presynaptic mediation. Neuropsychopharmacology 27, 301308.
  • Braida D., Limonta V., Malabarba L., Zani A. and Sala M. (2007) 5-HT1A receptors are envolved in the anxiolytic effect of Δ9-tetrahydrocannabinol and AM404, the anandamide transport inhibitor, in Sprague-Dawley rats. Eur. J. Pharmacol. 555, 156163.
  • Celada P., Puig M., Amargos-Bosch M., Adell A. and Artigas F. (2004) The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J. Psychiatry Neurosci. 9, 265.
  • Cheer J. F., Cadogan A. K., Marsden C. A., Fone K. C. and Kendall D. A. (1999) Modification of 5-HT2 receptor mediated behaviour in the rat by oleamide and the role of cannabinoid receptors. Neuropharmacology 38, 533541.
  • Darmani N. A. (2001) Cannabinoids of diverse structure inhibit two DOI-induced 5-HT(2A) receptor-mediated behaviors in mice. Pharmacol. Biochem. Behav. 68, 311317.
  • Darmani N. A. and Pandya D. K. (2000) Involvement of other neurotransmitters in behaviors induced by the cannabinoid CB1 receptor antagonist SR 141716A in naive mice. J. Neural Transm. 107, 931945.
  • Darmani N. A., Janoyan J. J., Kumar N. and Crim J. L. (2003) Behaviorally active doses of the CB1 receptor antagonist SR 141716A increase brain serotonin and dopamine levels and turnover. Pharmacol. Biochem. Behav. 75, 777787.
  • De Vry J. (1995) 5-HT1A receptor agonists: recent developments and controversial issues. Psychopharmacology (Berl) 121, 126.
  • Egashira N., Mishima K., Katsurabayashi S., Yoshitake T., Matsumoto Y., Ishida J., Yamaguchi M., Iwasaki K. and Fujiwara M. (2002) Involvement of 5-hydroxytryptamine neuronal system in Delta(9)-tetrahydrocannabinol-induced impairment of spatial memory. Eur. J. Pharmacol. 445, 221229.
  • Egashira N., Mishima K., Uchida T. et al. (2004) Anandamide inhibits the DOI-induced head-twitch response in mice. Psychopharmacology (Berl) 171, 382389.
  • Fernández-Ruiz J., Berrendero F., Hernandez M. L. and Ramos J. A. (2000) The endogenous cannabinoid system and brain development. Trends Neurosci. 23, 1420.
  • Fone K. C. F., Robinson A. J. and Marsden C. A. (1991) Characterisation of the 5-HT receptor subtypes involved in the motor behaviours produced by intrathecal administration of 5-HT agonists in rats. Br. J. Pharmacol. 103, 15471555.
  • Freund T. F., Katona I. and Piomelli D. (2003) Role of endogenous cannabinoids in synaptic signaling. Physiol. Rev. 83, 10171066.
  • Gobbi G., Bambico F. R., Mangieri R. et al. (2005) Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc. Natl Acad. Sci. USA 102, 1862018625.
  • Goodwin G. M., De Souza R. J. and Green A. R. (1985) The pharmacology of the hypothermic response in mice to 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). A model of presynaptic 5-HT1 function. Neuropharmacology 24, 11871194.
  • Gorzalka B. B., Hill M. N. and Sun J. C. (2005) Functional role of the endocannabinoid system and AMPA/kainate receptors in 5-HT2A receptor-mediated wet-dog shakes. Eur. J. Pharmacol. 516, 2833.
  • Gresch P. J., Smith R. L., Barrett R. J. and Sanders-Bush E. (2005) Behavioral tolerance to lysergic acide diethylamide is associated with reduced serotonin-2A receptor signalling in rat cortex. Neuropsychopharmacol. 30, 16931672.
  • Haller J., Varga B., Ledent C. and Freund T. F. (2004) CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents. Behav. Pharmacol. 15, 299304.
  • Hill M. N., Sun J. C., Tse M. T. and Gorzalka B. B. (2006a) Altered responsiveness of serotonin receptor subtypes following long-term cannabinoid treatment. Int. J. Neuropsychopharmacol. 9, 27786.
  • Hill M. N., Ho V. -S. V., Sinopoli K. J., Viau V., Hillard C. J. and Gorzalka B. B. (2006b) Involvement of the endocannabinoid system in the ability of long-term tryciclic antidepressant treatment to suppress stress-induced activation of the hypothalamic-pituitary-adrenal axis. Neuropsychopharmacology 31, 25912599.
  • Hoyer D., Clarke D. E., Fozard J. R., Hartig P. R., Martin G. R., Mylecharane E. J., Saxena P. R. and Humphrey P. P. (1994) International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol. Rev. 46, 157203.
  • Hungund B. L., Vinod K. Y., Kassir S. A., Basavarajappa B. S., Yalamanchili R., Cooper T. B., Mann J. J. and Arango V. (2004) Upregulation of CB1 receptors and agonist-stimulated [35S]GTPgammaS binding in the prefrontal cortex of depressed suicide victims. Mol. Psychiatry 9, 184190.
  • Jin K., Xie L., Kim S. H., Parmentier-Batteur S., Sun Y., Mao X. O., Childs J. and Greenberg D. A. (2004) Defective adult neurogenesis in CB1 cannabinoid receptor knockout mice. Mol. Pharmacol. 66, 204208.
  • Kathuria S., Gaetani S., Fegley D. et al. (2003) Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med. 9, 7681.
  • Kelai S., Hanoun N., Aufrere G., Beauge F., Hamon M. and Lanfumey L. (2006) Cannabinoid-serotonin interactions in alcohol-preferring vs. alcohol-avoiding mice. J. Neurochem. 99, 308320.
  • Ledent C., Valverde O., Cossu G. et al. (1999) Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283, 401404.
  • Lichtman A. H. and Martin B. R. (2005) Cannabinoid tolerance and dependence. Handb. Exp. Pharmacol. 168, 691717.
  • Malone D. T. and Taylor D. A. (2001) Involvement of somatodendritic 5-HT1A receptors in Δ9-tetrahydrocannabinol-induced hypothermia in the rat. Pharmacol. Biochem. Behav. 69, 595601.
  • Marco E. M., Pérez-Álvarez L., Borcel E., Rubio M., Guaza C., Ambrosio E., File S. E. and Viveros M. P. (2004) Involvement of 5-HT1A receptors in behavioural effects of the cannabinoid receptor agonist CP 55,940 in male rats. Behav. Pharmacol. 15, 2127.
  • Martín M., Ledent C., Parmentier M., Maldonado R. and Valverde O. (2002) Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology (Berl) 159, 379387.
  • Mato S., Rodríguez-Puertas R., González-Maeso J., Meana J., Salles J. and Pazos A. (2001) Cannabinoid receptors in postmortem human brain: a radiometric and transductional study in major depression. Br. J. Pharmacol. 134 (1P-199P), 161P.
  • Matsuda L. A., Lolait S. J., Brownstein M. J., Young A. C. and Bonner T. I. (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561564.
  • Meller E., Chalfin M. and Bohmaker K. (1992) Serotonin 5-HT1A receptor-mediated hypothermia in mice: absence of spare receptors and rapid induction of tolerance. Pharmacol. Biochem. Behav. 43, 405411.
  • Nakazi M., Bauer U., Nickell T., Kathmann M. and Schlicker E. (2000) Inhibition of serotonin release in the mouse brain via presynaptic cannabinoid CB1 receptors. Naunyn Schmiedebergs Arch. Pharmacol. 361, 1924.
  • Navarro M., Hernández E., Muñoz R. M., Del Arco I., Villanúa M. A., Carrera M. R. and Rodríguez de Fonseca F. (1997) Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport 8, 4916.
  • Oliva J. M., Urigüen L., Pérez-Rial S. and Manzanares J. (2005) Time course of opioid and cannabinoid gene transcription alterations induced by repeated administration with fluoxetine in the rat brain. Neuropharmacology 49, 618626.
  • Ong W. Y. and Mackie K. (1999) A light and electron microscopic study of the CB1 cannabinoid receptor in primate brain. Neuroscience 92, 11771191.
  • Parks C. L., Robinson P. S., Sibille E., Shenk T. and Toth M. (1998) Increased anxiety of mice lacking the serotonin1A receptor. Proc. Natl Acad. Sci. USA 95, 1073410739.
  • Patel S. and Hillard C. J. (2006) Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J. Pharmacol. Exp. Ther. 318, 304311.
  • Porsolt R. D., Le Pichon M. and Jalfre M. (1977) Depression: a new animal model sensitive to antidepressant treatments. Nature 266, 730732.
  • Shearman L. P., Rosko K. M., Fleischer R., Wang J., Xu S., Tong X. S. and Rocha B. A. (2003) Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice. Behav. Pharmacol. 14, 573582.
  • Sim-Selley L. J. (2003) Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. Crit. Rev. Neurobiol. 15, 91119.
  • Steru L., Chermat R., Thierry B. and Simon P. (1985) The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl) 85, 367370.
  • Stockmeier C. A., Shapiro L. A., Dilley G. E., Kolli T. N., Friedman L. and Rajkowska G. (1998) Increase in serotonin-1A autoreceptors in the midbrain of suicide victims with major depression-postmortem evidence for decreased serotonin activity. J. Neurosci. 18, 73947401.
  • Tzavara E. T., Davis R. J., Perry K. W., Li X., Salhoff C., Bymaster F. P., Witkin J. M. and Nomikos G. G. (2003) The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Br. J. Pharmacol. 138, 544553.
  • Urigüen L., Pérez-Rial S., Ledent C., Palomo T. and Manzanares J. (2004) Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors. Neuropharmacology 46, 966973.
  • Valverde O. (2005) Participation of the cannabinoid system in the regulation of emotional-like behaviour. Curr. Pharm. Des. 11, 34213429.
  • Wilson R. I. and Nicoll R. A. (2002) Endocannabinoid signaling in the brain. Science 296, 678682.
  • Yates M., Leake A., Candy J. M., Fairbairn A. F., McKeith I. G. and Ferrier I. N. (1990) 5-HT2 receptor changes in major depression. Biol. Psychiatry 27, 489496.